BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low – Should You Sell?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $8.50 and last traded at $8.70, with a volume of 6285 shares changing hands. The stock had previously closed at $8.91.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Raymond James Financial raised shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research report on Friday, January 9th. HC Wainwright increased their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Weiss Ratings assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Finally, Stifel Nicolaus assumed coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $26.00.

BridgeBio Oncology Therapeutics Trading Down 5.1%

The company has a market cap of $676.73 million, a price-to-earnings ratio of -5.57 and a beta of 0.51. The firm has a 50-day moving average of $10.19.

Institutional Trading of BridgeBio Oncology Therapeutics

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after buying an additional 20,385 shares during the last quarter. State Street Corp increased its position in shares of BridgeBio Oncology Therapeutics by 23.5% during the fourth quarter. State Street Corp now owns 218,278 shares of the company’s stock worth $2,733,000 after purchasing an additional 41,583 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth about $1,185,000. Renaissance Technologies LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth about $930,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth about $670,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.